I. Introduction
Breast cancer (BC), one of the most prevalent cancers and the leading cause of women’s mortality worldwide, is categorized by histological and molecular subtypes. Histologically, BC is categorized into invasive carcinoma-invasive ductal carcinoma (IDC), invasive lobular carcinoma (ILC), mucinous, tubular, medullary carcinoma, and in situ carcinoma-ductal carcinoma in situ (DCIS), and lobular carcinoma in situ (LCIS) [1]. Molecularly, it is classified as luminal A (ER-positive/PgR positive, HER2 negative, Ki%), luminal B (varying ER/PgR expression, HER2 positive, Ki%), HER2 enriched (ER and PgR negative, HER2 positive) and triple-negative breast cancer (TNBC- ER-negative, PgR negative, HER2 negative) [2]. These subtypes play a significant role in devising therapeutic regimens and predicting survival outcomes. Breast tumor heterogeneity due to the tumor microenvironment can vary across the tumor volume or between different tumor types. Intratumor heterogeneity is the coexistence of distinct subpopulations of tumor cells within the primary tumor [3].